We are live on ! Find out more
VKTX icon

Viking Therapeutics
VKTX

13 hedge funds and large institutions have $1.08M invested in Viking Therapeutics in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

16,889% more capital inflows, than outflows

Capital inflows: $1.08M | Capital outflows: $6.33K

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

18% more funds holding

Funds holding: 11 → 13 (+2)

4.22% more ownership

Funds ownership: 0.24% → 4.46% (+4.2%)

Holders
13
Holders Change
+2
Holders Change %
+18.18%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Sio Capital Management
Sio Capital Management
New York
+$731K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$244K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$41.2K
4
ARTA
A.R.T. Advisors
New York
+$26.8K
5
Northern Trust
Northern Trust
Illinois
+$22.4K

Top Sellers

Rank Fund Capital Flow
1
IFP Advisors
IFP Advisors
Florida
-$6K
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$328

VKTX Hedge Fund Activity: Q2 2016 in Review

13 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q2 2016, worth a combined $1.08M — up 1,406% from $72K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VKTX positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Sio Capital Management, opening a new position worth an estimated $731K. The largest seller was IFP Advisors, exiting entirely with an estimated $6K sold.

  • 13 institutional investors held Viking Therapeutics (VKTX) as of Q2 2016, up from 11 in Q1 2016.
  • Funds reported $1.08M of Viking Therapeutics stock for Q2 2016, up 1,406% quarter-over-quarter.
  • 5 funds opened new Viking Therapeutics positions in Q2 2016 and 3 closed out, a net change of +2 holders.
  • The largest Viking Therapeutics buyer in Q2 2016 was Sio Capital Management, an estimated $731K added.
  • The largest Viking Therapeutics seller in Q2 2016 was IFP Advisors, an estimated $6K sold.

Based on aggregated 13F filings for Q2 2016.